These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 24029645

  • 1. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
    Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O.
    Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
    [Abstract] [Full Text] [Related]

  • 2. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations.
    Liu Y, Li Y, Xu H, Zhou L, Yang X, Wang C.
    Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
    [Abstract] [Full Text] [Related]

  • 3. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ.
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [Abstract] [Full Text] [Related]

  • 4. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
    Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T.
    Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
    [Abstract] [Full Text] [Related]

  • 5. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ, Papathanassiou M, Anagnostou M, Thodou E, Tamposis I, Mitrakas L, Zachos I, Koukoulis GK, Samara M, Tzortzis V.
    F1000Res; 2023 Jan; 12():918. PubMed ID: 38933491
    [Abstract] [Full Text] [Related]

  • 6. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I, Maradeo ME, Dulaimi E, Cairns P.
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [Abstract] [Full Text] [Related]

  • 7. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S, Ohashi R, Moore AL, Rüschoff JH, Beisel C, Hermanns T, Mischo A, Corrò C, Beyer J, Beerenwinkel N, Moch H, Schraml P.
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [Abstract] [Full Text] [Related]

  • 8. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G.
    Oncotarget; 2015 Oct 13; 6(31):32161-8. PubMed ID: 26452128
    [Abstract] [Full Text] [Related]

  • 9. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
    Zeng H, Chen L, Wang M, Luo Y, Huang Y, Ma X.
    Aging (Albany NY); 2021 Mar 26; 13(7):9960-9975. PubMed ID: 33795526
    [Abstract] [Full Text] [Related]

  • 10. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R.
    Expert Rev Mol Diagn; 2015 Mar 26; 15(9):1201-10. PubMed ID: 26166446
    [Abstract] [Full Text] [Related]

  • 11. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J.
    Cancer J; 2013 Mar 26; 19(4):324-32. PubMed ID: 23867514
    [Abstract] [Full Text] [Related]

  • 12. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L, Testa JR, Yang H.
    Cancer Genet; 2015 May 26; 208(5):206-14. PubMed ID: 25873528
    [Abstract] [Full Text] [Related]

  • 13. Relationship between visceral adipose tissue and genetic mutations (VHL and KDM5C) in clear cell renal cell carcinoma.
    Greco F, Mallio CA.
    Radiol Med; 2021 May 26; 126(5):645-651. PubMed ID: 33400184
    [Abstract] [Full Text] [Related]

  • 14. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ, ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators.
    Clin Cancer Res; 2013 Jun 15; 19(12):3259-67. PubMed ID: 23620406
    [Abstract] [Full Text] [Related]

  • 15. Genomics and clinical correlates of renal cell carcinoma.
    Mitchell TJ, Rossi SH, Klatte T, Stewart GD.
    World J Urol; 2018 Dec 15; 36(12):1899-1911. PubMed ID: 30099580
    [Abstract] [Full Text] [Related]

  • 16. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
    Shinagare AB, Vikram R, Jaffe C, Akin O, Kirby J, Huang E, Freymann J, Sainani NI, Sadow CA, Bathala TK, Rubin DL, Oto A, Heller MT, Surabhi VR, Katabathina V, Silverman SG.
    Abdom Imaging; 2015 Aug 15; 40(6):1684-92. PubMed ID: 25753955
    [Abstract] [Full Text] [Related]

  • 17. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.
    Urol Oncol; 2017 Aug 15; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [Abstract] [Full Text] [Related]

  • 18. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ.
    Lancet Oncol; 2018 Dec 15; 19(12):1688-1698. PubMed ID: 30416077
    [Abstract] [Full Text] [Related]

  • 19. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.
    Randall JM, Millard F, Kurzrock R.
    Cancer Metastasis Rev; 2014 Dec 15; 33(4):1109-24. PubMed ID: 25365943
    [Abstract] [Full Text] [Related]

  • 20. Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
    Kocak B, Durmaz ES, Ates E, Ulusan MB.
    AJR Am J Roentgenol; 2019 Mar 15; 212(3):W55-W63. PubMed ID: 30601030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.